BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 26637774)

  • 21. OCT2 expression in histiocytoses.
    Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
    Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
    Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histiocytosis.
    Rocamora-Blanch G; Climent F; Solanich X
    Med Clin (Barc); 2023 Aug; 161(4):166-175. PubMed ID: 37263840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group].
    Adam Z; Szturz P; Pour L; Krejčí M; Zahradová L; Tomíška M; Král Z; Koukalová R; Rehák Z; Mayer J
    Vnitr Lek; 2012 Jun; 58(6):455-65. PubMed ID: 22913238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CNS Erdheim-Chester Disease: A Challenge to Diagnose.
    Pan Z; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Dec; 76(12):986-996. PubMed ID: 29096034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016.
    Tzankov A; Kremer M; Leguit R; Orazi A; van der Walt J; Gianelli U; Hebeda KM
    Ann Hematol; 2018 Nov; 97(11):2117-2128. PubMed ID: 30084011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Musculoskeletal imaging features of non-Langerhans cell histiocytoses.
    Choraria A; Andrei V; Rajakulasingam R; Saifuddin A
    Skeletal Radiol; 2021 Oct; 50(10):1921-1940. PubMed ID: 33787962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histiocytosis and the nervous system: from diagnosis to targeted therapies.
    Cohen Aubart F; Idbaih A; Emile JF; Amoura Z; Abdel-Wahab O; Durham BH; Haroche J; Diamond EL
    Neuro Oncol; 2021 Sep; 23(9):1433-1446. PubMed ID: 33993305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes.
    Banks SA; Bhatti MT; Go RS; Abeykoon JP; Acosta-Medina AA; Hazim AZ; Goyal G; Young JR; Koster MJ; Vassallo R; Ryu JH; Davidge-Pitts CJ; Ravindran A; Sartori Valinotti JC; Bennani NN; Shah MV; Rech KL; Garrity JA; Tobin WO;
    Ophthalmology; 2023 Jan; 130(1):77-86. PubMed ID: 35932838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erdheim-Chester Disease Involving the Left Uterine Adnexa: Mimicking an Ovarian Carcinoma Clinically.
    Zeng Y; Wang Q; Wang X; Jiang X; Yao H; Tang X
    Int J Surg Pathol; 2023 Dec; 31(8):1532-1537. PubMed ID: 36855299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
    Geerlinks AV; Abla O
    Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
    Kim S; Lee M; Shin HJ; Lee J; Suh YL
    Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
    Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
    Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.